Red>AstraZeneca (AZN): Q4 EPS of $1.56 beats by $0.21. Revenues of $7.28B (-16% Y/Y) beat by $80M.
Profit excluding items -8% to $1.94B, with a patent cliff hurting earnings in Q4 and expected to continue to do so this year. As such, AstraZeneca warns of a "mid-to-high single digit percentage decline in revenue for 2013," (vs consensus of -3%) and that earnings will drop "significantly more than revenue" as operating costs rise.
Market Data 
Markets 
AI
